APLS
Price
$19.28
Change
-$0.19 (-0.98%)
Updated
Jul 21, 04:59 PM (EDT)
Capitalization
2.45B
21 days until earnings call
PMCB
Price
$1.00
Change
-$0.03 (-2.91%)
Updated
Jul 21, 04:57 PM (EDT)
Capitalization
7.07M
35 days until earnings call
Interact to see
Advertisement

APLS vs PMCB

Header iconAPLS vs PMCB Comparison
Open Charts APLS vs PMCBBanner chart's image
Apellis Pharmaceuticals
Price$19.28
Change-$0.19 (-0.98%)
Volume$13.03K
Capitalization2.45B
PharmaCyte Biotech
Price$1.00
Change-$0.03 (-2.91%)
Volume$400
Capitalization7.07M
APLS vs PMCB Comparison Chart in %
Loading...
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMCB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APLS vs. PMCB commentary
Jul 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APLS is a Hold and PMCB is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 22, 2025
Stock price -- (APLS: $19.47 vs. PMCB: $1.03)
Brand notoriety: APLS and PMCB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: APLS: 86% vs. PMCB: 275%
Market capitalization -- APLS: $2.45B vs. PMCB: $7.07M
APLS [@Biotechnology] is valued at $2.45B. PMCB’s [@Biotechnology] market capitalization is $7.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APLS’s FA Score shows that 0 FA rating(s) are green whilePMCB’s FA Score has 1 green FA rating(s).

  • APLS’s FA Score: 0 green, 5 red.
  • PMCB’s FA Score: 1 green, 4 red.
According to our system of comparison, PMCB is a better buy in the long-term than APLS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APLS’s TA Score shows that 6 TA indicator(s) are bullish while PMCB’s TA Score has 3 bullish TA indicator(s).

  • APLS’s TA Score: 6 bullish, 3 bearish.
  • PMCB’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, APLS is a better buy in the short-term than PMCB.

Price Growth

APLS (@Biotechnology) experienced а +0.15% price change this week, while PMCB (@Biotechnology) price change was -4.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.21%. For the same industry, the average monthly price growth was +15.57%, and the average quarterly price growth was +33.92%.

Reported Earning Dates

APLS is expected to report earnings on Aug 11, 2025.

PMCB is expected to report earnings on Aug 25, 2025.

Industries' Descriptions

@Biotechnology (+2.21% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
APLS($2.45B) has a higher market cap than PMCB($7.07M). PMCB YTD gains are higher at: -34.395 vs. APLS (-38.985). PMCB has higher annual earnings (EBITDA): -4.5M vs. APLS (-176.08M). APLS has more cash in the bank: 358M vs. PMCB (16.8M). PMCB has less debt than APLS: PMCB (75.2K) vs APLS (470M). APLS has higher revenues than PMCB: APLS (776M) vs PMCB (0).
APLSPMCBAPLS / PMCB
Capitalization2.45B7.07M34,611%
EBITDA-176.08M-4.5M3,911%
Gain YTD-38.985-34.395113%
P/E RatioN/A0.77-
Revenue776M0-
Total Cash358M16.8M2,131%
Total Debt470M75.2K625,000%
FUNDAMENTALS RATINGS
APLS vs PMCB: Fundamental Ratings
APLS
PMCB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
10
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9835
PRICE GROWTH RATING
1..100
6287
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PMCB's Valuation (10) in the null industry is somewhat better than the same rating for APLS (70) in the Medical Distributors industry. This means that PMCB’s stock grew somewhat faster than APLS’s over the last 12 months.

PMCB's Profit vs Risk Rating (100) in the null industry is in the same range as APLS (100) in the Medical Distributors industry. This means that PMCB’s stock grew similarly to APLS’s over the last 12 months.

PMCB's SMR Rating (35) in the null industry is somewhat better than the same rating for APLS (98) in the Medical Distributors industry. This means that PMCB’s stock grew somewhat faster than APLS’s over the last 12 months.

APLS's Price Growth Rating (62) in the Medical Distributors industry is in the same range as PMCB (87) in the null industry. This means that APLS’s stock grew similarly to PMCB’s over the last 12 months.

PMCB's P/E Growth Rating (98) in the null industry is in the same range as APLS (100) in the Medical Distributors industry. This means that PMCB’s stock grew similarly to APLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APLSPMCB
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
74%
Bearish Trend 4 days ago
81%
Momentum
ODDS (%)
Bullish Trend 4 days ago
84%
Bearish Trend 4 days ago
88%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bearish Trend 4 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
70%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
Bullish Trend 6 days ago
75%
Declines
ODDS (%)
Bearish Trend 22 days ago
79%
Bearish Trend 11 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
79%
Bullish Trend 4 days ago
74%
Aroon
ODDS (%)
Bullish Trend 4 days ago
85%
Bearish Trend 4 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
APLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PMCB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BEN24.600.08
+0.33%
Franklin Resources
SEPN12.55-0.07
-0.55%
Septerna Inc
AIMD2.77-0.03
-1.07%
AINOS Inc
EVTC33.28-0.43
-1.28%
EVERTEC
LARK26.25-0.40
-1.50%
Landmark Bancorp

APLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, APLS has been loosely correlated with ROIV. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if APLS jumps, then ROIV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APLS
1D Price
Change %
APLS100%
-2.84%
ROIV - APLS
48%
Loosely correlated
-1.80%
ARWR - APLS
46%
Loosely correlated
-11.09%
IMVT - APLS
45%
Loosely correlated
-2.02%
DNLI - APLS
44%
Loosely correlated
-3.65%
KYMR - APLS
44%
Loosely correlated
-0.37%
More

PMCB and

Correlation & Price change

A.I.dvisor tells us that PMCB and CRBP have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PMCB and CRBP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PMCB
1D Price
Change %
PMCB100%
+0.98%
CRBP - PMCB
31%
Poorly correlated
-0.23%
APLS - PMCB
25%
Poorly correlated
-2.84%
XBIT - PMCB
24%
Poorly correlated
-0.67%
FBIO - PMCB
22%
Poorly correlated
+1.04%
SER - PMCB
22%
Poorly correlated
+0.94%
More